Burns J W & Co. Inc. NY Sells 1,222 Shares of Novartis AG (NYSE:NVS)

Burns J W & Co. Inc. NY trimmed its position in shares of Novartis AG (NYSE:NVS) by 15.3% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 6,787 shares of the company’s stock after selling 1,222 shares during the quarter. Burns J W & Co. Inc. NY’s holdings in Novartis were worth $660,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the business. Steigerwald Gordon & Koch Inc. increased its position in shares of Novartis by 4.8% during the 3rd quarter. Steigerwald Gordon & Koch Inc. now owns 2,091 shares of the company’s stock valued at $241,000 after purchasing an additional 95 shares during the last quarter. Centaurus Financial Inc. grew its position in Novartis by 1.7% during the third quarter. Centaurus Financial Inc. now owns 5,728 shares of the company’s stock valued at $659,000 after buying an additional 98 shares during the period. FLC Capital Advisors increased its holdings in Novartis by 4.4% during the third quarter. FLC Capital Advisors now owns 2,366 shares of the company’s stock worth $272,000 after buying an additional 100 shares during the last quarter. Clear Harbor Asset Management LLC boosted its stake in Novartis by 2.3% in the third quarter. Clear Harbor Asset Management LLC now owns 4,423 shares of the company’s stock valued at $509,000 after acquiring an additional 100 shares during the last quarter. Finally, Allen Wealth Management LLC grew its position in shares of Novartis by 1.8% during the 3rd quarter. Allen Wealth Management LLC now owns 5,788 shares of the company’s stock valued at $666,000 after acquiring an additional 100 shares during the period. 13.12% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

NVS has been the topic of a number of research reports. HSBC cut Novartis from a “hold” rating to a “reduce” rating in a research note on Wednesday, December 4th. BMO Capital Markets upped their target price on Novartis from $118.00 to $120.00 and gave the stock a “market perform” rating in a research note on Wednesday, October 30th. Finally, Erste Group Bank reissued a “hold” rating on shares of Novartis in a research note on Tuesday, November 19th. Two analysts have rated the stock with a sell rating and seven have given a hold rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $121.50.

Novartis Stock Up 0.1 %

NVS stock traded up $0.12 during midday trading on Monday, hitting $99.20. The stock had a trading volume of 1,463,879 shares, compared to its average volume of 1,410,495. The business has a 50-day moving average of $101.55 and a two-hundred day moving average of $109.29. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.11 and a quick ratio of 0.90. The firm has a market cap of $202.76 billion, a price-to-earnings ratio of 11.52, a price-to-earnings-growth ratio of 1.49 and a beta of 0.57. Novartis AG has a 52-week low of $92.35 and a 52-week high of $120.92.

Novartis (NYSE:NVS) last posted its quarterly earnings data on Tuesday, October 29th. The company reported $2.06 earnings per share for the quarter, beating analysts’ consensus estimates of $1.94 by $0.12. Novartis had a return on equity of 34.80% and a net margin of 35.96%. The company had revenue of $12.82 billion during the quarter, compared to analyst estimates of $12.62 billion. During the same quarter last year, the company earned $1.74 EPS. As a group, equities research analysts forecast that Novartis AG will post 7.65 earnings per share for the current fiscal year.

Novartis Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.